Why Syndax Pharmaceuticals, Inc.’s (SNDX) Stock Is Down 16.74%
As of Tuesday, October 13, Syndax Pharmaceuticals, Inc.’s SNDX share price has dipped by 16.74%, which has investors questioning if this is right time to buy.Tudor Pop
Stock Evaluator: Syndax Pharmaceuticals, Inc. (SNDX)
Syndax Pharmaceuticals, Inc. SNDX
$13.65
-0.50
-3.53%
October 30, 2026 4:00:00 PM
EST
Volume: 2,539,611
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Commentary & Analysis
Why Syndax Pharmaceuticals, Inc.’s (SNDX) Stock Is Down 5.62%
As of Thursday, September 10, Syndax Pharmaceuticals, Inc.’s SNDX share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Is Syndax Pharmaceuticals, Inc. (SNDX) Overvalued?
We dive into why Syndax Pharmaceuticals, Inc. (SNDX) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Michael Rose
What You Need to Know About Syndax Pharmaceuticals, Inc.'s Q3 Earnings
Syndax Pharmaceuticals, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (SNDX) missed or beat analyst's expectations.Tudor Pop
Why Syndax Pharmaceuticals, Inc.’s (SNDX) Stock Is Down 5.41%
As of Tuesday, July 28, Syndax Pharmaceuticals, Inc.’s SNDX share price has dipped by 5.41%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | SNDX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,217.1 | $226.9 | 48% |
|
| Shares Out (Mil) | 89.0 | 53.4 | 60% |
|
| Institutional Ownership | 99.1% | 92.9% | 85% |
|
| Float (Mil) | 80.3 | 40.7 | 56% |
|
| Beta | 0.37 | 0.95 | 21% |
|
| Avg Daily Volume (000s) | 3,017 | 469 | 87% |
|
| Price Change (52-week) |
3.1% | 46.6% | 54% |
|
| Growth | SNDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 158.3% | 12.8% | 99% |
|
| Net Income (5yr) | (31.3%) | (10.1%) | 13% |
|
| EPS (5yr) | (12.0%) | 15.8% | 20 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.0%) | (15.7%) | 46% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 11 | |
| Current EPS | ($0.484) | ($1.951) | ($0.732) | |
| Month Ago EPS | ($0.470) | ($1.935) | ($0.816) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.363) | ($1.602) | ($0.364) | |
| Year/Year Chg | (12.8%) | (40.8%) | (117.4%) | |
| Financials | SNDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $252 | $37 | 34% |
|
| Net Income (TTM) (Mil) | ($221) | ($44) | 6% |
|
| EPS (TTM) | ($2.514) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($221) | ($33) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $228 | $2 | 85% |
|
| Long-Term Debt (Q1) (Mil) | $589 | $4 | 61% |
|
| Enterprise Value (Q1) (Mil) | $1,814 | $174 | 48% |
|
| Valuation | SNDX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 80.18 | 2.17 | 99% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SNDX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (8.0%) | 65.6% | 4% |
|
| Net Margin | (87.5%) | (71.5%) | 8% |
|
| ROA | (34.0%) | (47.1%) | 15% |
|
| ROE | (255.9%) | (53.0%) | 3% |
|
| Liabilities to Assets | 97.9% | 29.6% | 94% |
|
| F-Score | 5 | 2 | 50% |
|
Syndax Pharmaceuticals, Inc. did not pass any screens on 10/30/2026.
